Valuation: Novelix Pharmaceuticals Limited

Market Cap 1.11B 11.69M 10.15M 9.46M 8.69M 16.44M 16.62M 112M 43.62M 556M 43.9M 42.94M 1.84B P/E 2024
1,719x
P/E 2025 296x
Enterprise Value 1.11B 11.62M 10.09M 9.41M 8.64M 16.34M 16.52M 111M 43.35M 552M 43.63M 42.68M 1.83B EV / Sales 2024
2.32x
EV / Sales 2025 0.84x
Free-Float
24.95%
Yield 2024 *
-
Yield 2025 -
07-08 Novelix Pharmaceuticals Limited announced that it has received INR 68.4 million in funding CI
06-03 Novelix Pharmaceuticals Limited announced that it expects to receive INR 68.4 million in funding CI
05-29 Novelix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2026 CI
03-30 Novelix Pharmaceuticals Limited Announces Resignation of Jivamohan Divakar Valluri as Non-Executive Director and Changes in Committee Composition, Effective March 30, 2026 CI
02-12 Novelix Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
02-11 Novelix Pharmaceuticals Limited announced that it has received INR 139.2 million in funding CI
01-10 Novelix Pharmaceuticals Limited Confirms Appointment of Sridevi Belide as Non-Executive Non-Independent Director CI
12-10 Novelix Pharmaceuticals Limited announced that it expects to receive INR 150 million in funding CI
11-13 Novelix Pharmaceuticals Limited Announces Board and Committee Changes, Effective 13 November, 2025 CI
25-10-23 Novelix Pharmaceuticals Limited Appoints Sridevi Belide as an Additional Director (Non-Executive Non-Independent), Effective October 23, 2025 CI
25-10-22 Novelix Pharmaceuticals Limited announced that it expects to receive INR 33.22 million in funding from Srinidhi Fine-Chemicals LLP CI
25-10-17 Novelix Pharmaceuticals signs agreement with GMBU E.V., Halle for astaxanthin RE
25-10-16 Novelix Pharmaceuticals collaborates with GMBU E.V., Halle (Saale), Germany RE
1 day-3.18%
1 week-0.65%
Current month-1.35%
1 month-7.65%
3 months+26.94%
6 months+9.72%
Current year+9.47%
1 week 67
Extreme 67
72.57
1 month 63.19
Extreme 63.19
77
Current year 49.01
Extreme 49.01
92
1 year 38
Extreme 38
92
3 years 8
Extreme 8
92
5 years 5.38
Extreme 5.38
92
10 years 1.85
Extreme 1.85
92
Manager TitleAgeSince
Director of Finance/CFO - 2025-02-11
Compliance Officer - 2019-03-31
Director TitleAgeSince
Director/Board Member - 2024-09-01
Director/Board Member - 2024-09-01
Director/Board Member - 2025-02-11
Change 5-day change 1-year change 3-year change Capi.($)
-3.18%-0.65%+67.24%+621.58% 15.69M
+2.75%+2.58%+53.54%+144.44% 341B
+2.52%+1.90%+45.03%+198.11% 319B
+2.47%+3.32%+48.64%+199.43% 230B
+0.45%+0.36%+9.53%+63.82% 185B
-0.96%-0.32%-3.15%+13.36% 59.65B
-1.70%+3.46%-5.43%+53.20% 27.89B
+2.87%-0.89%+56.35%+183.26% 28.1B
+1.47%+8.66%+121.40%+202.17% 28.4B
+1.45%-0.08%-7.54%+28.79% 26.76B
Average +0.58%+1.32%+38.56%+170.82% 124.54B
Weighted average by Cap. +1.37%+1.03%+40.18%+147.73%

Financials

2024 2025
Net sales 44.95M 473K 410K 383K 351K 665K 672K 4.51M 1.76M 22.47M 1.77M 1.74M 74.45M 307M 3.23M 2.81M 2.62M 2.4M 4.54M 4.59M 30.84M 12.06M 154M 12.13M 11.87M 509M
Net income 104K 1.09K 950.43 886.16 814.07 1.54K 1.56K 10.45K 4.08K 52.05K 4.11K 4.02K 172K 845K 8.89K 7.72K 7.19K 6.61K 12.5K 12.64K 84.81K 33.15K 423K 33.37K 32.64K 1.4M
Net Debt -34.91M -367K -319K -297K -273K -516K -522K -3.5M -1.37M -17.45M -1.38M -1.35M -57.82M -6.79M -71.34K -61.95K -57.76K -53.06K -100K -101K -681K -266K -3.39M -268K -262K -11.24M
Logo Novelix Pharmaceuticals Limited
Novelix Pharmaceuticals Ltd, formerly Trimurthi Limited, is an India-based company, which is engaged in the business of trading pharmaceuticals and related products and is in the business of trading shares and securities. The Company's segments include Pharma Business, Investment is Shares, Trading in shares, Foods, and Finance.
Employees
8
Date Price Change Volume
26-08-05 68.55 -3.18% 2,427
26-08-04 ₹70.80 +5.00% 2,203
26-08-03 ₹67.43 -2.96% 2,720
26-07-31 ₹69.49 +0.36% 2,685
26-07-30 ₹69.24 +0.35% 1,744
  1. Stock Market
  2. Stocks
  3. TRIMURTHI6 Stock